Loading…
Lobbying Income
$27.8M
Filings
796
Unique Clients
40
Active Period
2019–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Alternatives to PAIN Act
2026 · third_quarter · Client: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1227
Alternatives to PAIN Act
2026 · third_quarter · Client: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Client expense: — · Firm income: $60,000
Matched citations: S.475
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: SANOFI U.S. SERVICES, INC.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Drug Competition Enhancement Act
2026 · third_quarter · Client: SANOFI U.S. SERVICES, INC.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · third_quarter · Client: SANOFI U.S. SERVICES, INC.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1492
Drug Competition Enhancement Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $40,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · third_quarter · Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $40,000
Matched citations: S.1041
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: PFIZER, INC.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · third_quarter · Client: PFIZER, INC.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Humane Cosmetics Act of 2025
2026 · third_quarter · Client: PERSONAL CARE PRODUCTS COUNCIL
Issues related to animal testing, including H.R.1657-Humane Cosmetics Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R.1657
Consolidated Appropriations Act, 2026
2026 · third_quarter · Client: GRAIL, Inc.
Issues related to cancer screening, including the implementation of Section 6221 of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7148
Issues related to the World Trade Organization and digital trade rules. S.1705 - Chip Security Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1705
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: GENENTECH INC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Consolidated Appropriations Act, 2026
2026 · third_quarter · Client: GENENTECH INC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7148
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · third_quarter · Client: GENENTECH INC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).
Client expense: — · Firm income: $60,000
Matched citations: H.R.1476
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Client: AMGEN USA, INC.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1492
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · third_quarter · Client: AMGEN USA, INC.
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
SPEED Act
2026 · third_quarter · Client: AIRPORTS COUNCIL INTERNATIONAL -- NORTH AMERICA
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.4776
ALERT Act
2026 · third_quarter · Client: AIRPORTS COUNCIL INTERNATIONAL -- NORTH AMERICA
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7613
Pilot and Aircraft Privacy Act
2026 · third_quarter · Client: AIRPORTS COUNCIL INTERNATIONAL -- NORTH AMERICA
Issues related to airport infrastructure financing, and the use of fluorinated firefighting foam at airports. Issues related to air traffic control and facility upgrades. Issues related to airport safety, including S.2175 - Pilot and Aircraft Privacy Act, S.2503 - ROTOR Act, and H.R.7613 - ALERT Act. Issues related to federal permitting reform, including H.R.4776 - SPEED Act.
Client expense: — · Firm income: $60,000
Matched citations: S.2175
Source: Senate LDA